Exercise-responsive circulating miR-29a-3p attacked armored and cold tumors by inhibiting B7 homolog 3 (B7-H3) expression and then promoted the infiltration of tumor-infiltrating immune cells (TIICs), thereby boosting anti-B7-H3 therapeutic response. This evidence concerns the gene CD276 and neoplasm.